Imunon, Inc. Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value
Imunon, Inc. (IMNN) had Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value of $0 as of 2012-12-31, per its 10-K filed 2013-03-18.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue · last filed 2013-03-18
- 2012-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $0.00.
- 2012-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $137.59K.
- 2011-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $0.00.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value |
|---|---|
| 2012-12-31 | $0.00 10-K · filed 2013-03-18 |
| 2012-09-30 | $137.59K 10-Q · filed 2012-11-09 |
| 2011-12-31 | $0.00 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |